BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 7, 2005
View Archived Issues
EpiCept To Take Maxim In $136M Stock Buyout
Privately held pain drug firm EpiCept Corp. entered a deal to pay about $136 million in stock to take over Maxim Pharmaceuticals Inc., and the agreement is expected to close in the fourth quarter. (BioWorld Today)
Read More
Cephalon Files For Clearance Of OraVescent Fentanyl Tablet
Read More
Chiron Turns Down Novartis' Buyout Offer At $40 Per Share
Read More
PDL's Stock Rises On Ularitide Phase II Data, Analyst Upgrade
Read More
Other News To Note
Read More